The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
A grandmother, diagnosed with breast cancer, and her toddler granddaughter, diagnosed with acute myeloid leukemia, are facing ...
Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...
A donut-eating contest helped raise funds for 17-year-old Levi Atkins, who's battling Acute Myeloid Leukemia, while uniting ...
The University of Connecticut’s athletic department will host four separate bone marrow registry drives throughout November. The drives were organized in honor of 8-year-old Ben Rabinowitz, who was ...
In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...
"When you know that your granddaughter, who at that point wasn't even a year old, has already done that treatment, it made me ...
7don MSN
Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...
Moleculin Biotech (MBRX) announced new findings supporting the ability of Annamycin to overcome resistance to Venetoclax in acute myeloid leukemia. This includes data from preclinical in vitro studies ...
A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback